BC
Brandon Cieniewicz
CERo Therapeutics, Stanford University, Stony Brook University, University of Richmond
Research areas: Medicine · Oncology · Immunotherapy and Immune Responses · CAR-T cell therapy research · T-cell and B-cell Immunology
0000-0003-3268-7444
Employment
-
CERo Therapeutics Principal Scientist2020 - Present
-
Stanford University Postdoctoral Scholar2016 - 2020
Education
-
Stony Brook University Ph. D.2009 - 2015
-
University of Richmond B.S. Biology2005 - 2009
Projects & Funding
-
Understanding Type 1 T regulatory cell (Tr1) recognition and killing of Acute Myeloid Leukemia Children's Health Research Institute2018 - 2018
Publications (9)
- Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia Save
- Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia Save
- Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia Save
- Supplementary Data 1 from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia Save
- Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia Save
- Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia Save
- Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation Save
- IKKalpha-Mediated Non-canonical NF-kappaB Signaling is Required to Support Murine Gammaherpesvirus 68 LatencyIn Vivo Save
- Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients Save